These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9548483)

  • 41. Novel NFAT sites that mediate activation of the interleukin-2 promoter in response to T-cell receptor stimulation.
    Rooney JW; Sun YL; Glimcher LH; Hoey T
    Mol Cell Biol; 1995 Nov; 15(11):6299-310. PubMed ID: 7565783
    [TBL] [Abstract][Full Text] [Related]  

  • 42. N-substituted benzamides inhibit nuclear factor-kappaB and nuclear factor of activated T cells activity while inducing activator protein 1 activity in T lymphocytes.
    Lindgren H; Pero RW; Ivars F; Leanderson T
    Mol Immunol; 2001 Aug; 38(4):267-77. PubMed ID: 11566320
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Suppression of the interleukin-2 gene expression by aflatoxin B1 is mediated through the down-regulation of the NF-AT and AP-1 transcription factors.
    Han SH; Jeon YJ; Yea SS; Yang KH
    Toxicol Lett; 1999 Jul; 108(1):1-10. PubMed ID: 10472804
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The CD40L promoter contains nuclear factor of activated T cells-binding motifs which require AP-1 binding for activation of transcription.
    Tsytsykova AV; Tsitsikov EN; Geha RS
    J Biol Chem; 1996 Feb; 271(7):3763-70. PubMed ID: 8631992
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CTLA4 ligation attenuates AP-1, NFAT and NF-kappaB activity in activated T cells.
    Fraser JH; Rincón M; McCoy KD; Le Gros G
    Eur J Immunol; 1999 Mar; 29(3):838-44. PubMed ID: 10092086
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alterations in transcription factor binding at the IL-2 promoter region in anergized human CD4+ T lymphocytes.
    Heisel O; Keown P
    Transplantation; 2001 Oct; 72(8):1416-22. PubMed ID: 11685114
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Repression of IL-2 promoter activity by the novel basic leucine zipper p21SNFT protein.
    Iacobelli M; Wachsman W; McGuire KL
    J Immunol; 2000 Jul; 165(2):860-8. PubMed ID: 10878360
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Signal integration by transcription-factor assemblies: interactions of NF-AT1 and AP-1 on the IL-2 promoter.
    Chen L; Rao A; Harrison SC
    Cold Spring Harb Symp Quant Biol; 1999; 64():527-31. PubMed ID: 11232329
    [No Abstract]   [Full Text] [Related]  

  • 49. The interleukin 2 receptor alpha chain/CD25 promoter is a target for nuclear factor of activated T cells.
    Schuh K; Twardzik T; Kneitz B; Heyer J; Schimpl A; Serfling E
    J Exp Med; 1998 Oct; 188(7):1369-73. PubMed ID: 9763616
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transcriptional regulation of Fas gene expression by GA-binding protein and AP-1 in T cell antigen receptor.CD3 complex-stimulated T cells.
    Li XR; Chong AS; Wu J; Roebuck KA; Kumar A; Parrillo JE; Rapp UR; Kimberly RP; Williams JW; Xu X
    J Biol Chem; 1999 Dec; 274(49):35203-10. PubMed ID: 10575005
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regulation of mouse delta-opioid receptor gene transcription: involvement of the transcription factors AP-1 and AP-2.
    Wöltje M; Kraus J; Höllt V
    J Neurochem; 2000 Apr; 74(4):1355-62. PubMed ID: 10737590
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transcriptional regulation of the IL-5 gene in peripheral T cells of asthmatic patients.
    Ogawa K; Kaminuma O; Okudaira H; Kikkawa H; Ikezawa K; Sakurai N; Mori A
    Clin Exp Immunol; 2002 Dec; 130(3):475-83. PubMed ID: 12452838
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites.
    Shapiro VS; Truitt KE; Imboden JB; Weiss A
    Mol Cell Biol; 1997 Jul; 17(7):4051-8. PubMed ID: 9199340
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Coordinate and cooperative roles for NF-AT and AP-1 in the regulation of the murine IL-4 gene.
    Rooney JW; Hoey T; Glimcher LH
    Immunity; 1995 May; 2(5):473-83. PubMed ID: 7749982
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of proteins that interact with the IL-2 regulatory region in patients with rheumatic diseases.
    Becker H; Stengl G; Stein M; Federlin K
    Clin Exp Immunol; 1995 Mar; 99(3):325-30. PubMed ID: 7882553
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily.
    von Bülow GU; Bram RJ
    Science; 1997 Oct; 278(5335):138-41. PubMed ID: 9311921
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of NF-κB by opioids in T cells.
    Börner C; Kraus J
    J Immunol; 2013 Nov; 191(9):4640-7. PubMed ID: 24068670
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Constitutive binding of the transcription factor interleukin-2 (IL-2) enhancer binding factor to the IL-2 promoter.
    Nirula A; Moore DJ; Gaynor RB
    J Biol Chem; 1997 Mar; 272(12):7736-45. PubMed ID: 9065434
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 3-(13-Hydroxytridecyl)-1-[13-(3-pyridyl)tridecyl]pyridinium chloride (YM-53792), a novel inhibitor of NF-AT activation.
    Kuromitsu S; Fukunaga M; Lennard AC; Masuho Y; Nakada S
    Biochem Pharmacol; 1997 Nov; 54(9):999-1005. PubMed ID: 9374420
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IL-2 and IL-15 manifest opposing effects on activation of nuclear factor of activated T cells.
    Eicher DM
    Cell Immunol; 2003 Jun; 223(2):133-42. PubMed ID: 14527511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.